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The study published in Biology of Reproduction by Dragovic et al. [1] is the first study using multicolor flow cytometry applying directly conjugated antibodies to phenotype STBMs together with EVs from cells circulating in the vascular compartment. STBMs and their potential role in normal pregnancy and preeclampsia have previously been studied using flow cytometry based on different syncytiotrophoblast-specific antibodies. In most of these studies, indirect antibody labeling was applied, which compared to direct labeling is more susceptible to nonspecific binding. Systemic inflammation, which is a characteristic feature of preeclampsia, leads to activation of cells circulating in maternal blood, including leukocytes, endothelium, platelets, and red blood cells (RBCs), with increased release of EVs. Therefore, Dragovic et al. decided to explore EVs of these cells together with STBMs in samples of platelet-free plasma in nonpregnant controls, normal pregnant women, and women with lateonset preeclampsia. Correct identification of the proper phenotype is crucial for any study on quantification and functional characterization of STBMs and EVs, both because the STBMs in plasma from pregnant women only account for a minor fraction of all EVs and because considerable crossreactivity exists with blood cell-derived EVs. This identification was achieved by multicolor flow cytometry using directly conjugated antibodies targeting multiple markers of EVs. This very unique approach reduces the problem of unspecific binding.
For the development of this assay, EVs were prepared in vitro from pure populations of leukocytes, endothelium, platelets, and RBCs and were examined for suitable antibodies to analyze the corresponding EVs in vivo. Antibody labeling of EVs was compared to parent cells, and each marker was tested for cross-reactivity with STBMs. STBMs were prepared in vitro from maternal-side eluate of dual-perfused placental lobes. It has been shown previously that this elegant method is superior to other in vitro techniques, such as mechanical dissection of placental tissue or culture of villous explants, in providing functionally intact STBMs. Based on the in vitro data, a panel of markers was defined for in vivo characterization of STBMs simultaneously with EVs of the different intravascular cell types using flow cytometry. EVs including STBMs were prepared by ultracentrifugation of platelet-free plasma samples from three groups of women: nonpregnant controls, normal pregnant women, and women with late-onset preeclampsia. After labeling with two separate antibody panels, the EVs were subjected to flow cytometry. The first panel with three colorlabeled antibodies aimed to identify the placental-derived EVs; the second panel with five color-labeled antibodies was shown to be very effective in identifying EVs derived from platelets, RBCs, leukocytes, and endothelial cells.
Flow cytometry as used in most studies on EVs can only detect particles of 500 nm or larger. Nanoparticle Tracking Analysis (NTA) measures vesicle size and concentration based on light scatter and can quantify nanoparticles down to 40 nm. This fairly recent technology is used in the Dragovic et al. study for the first time to size and count EVs in plasma during pregnancy. The number of EVs detected with NTA was two orders of magnitude higher than with flow cytometry. EVs comprise microvesicles and exosomes. Microvesicles, which are generated by direct budding and shedding of plasma membrane, measure between 100 nm and 1 lm. Exosomes are considerably smaller (30-100 nm) and are generated by reverse budding of the endosome membrane forming multivesicular bodies, which fuse with the cell membrane. Release occurs by exocytosis. In the nonpregnant group, the number of EVs detected by NTA was also much higher than what was found with flow cytometry. Different from the analysis with flow cytometry, the EV count by NTA in the two pregnancy groups was significantly higher compared to that in the nonpregnant controls. The finding that the large majority of particles detected by NTA are in a size range that is undetectable by flow cytometry is novel and of considerable interest. At present, however, a further characterization of these nanoparticles, especially whether they are of cellular origin, cannot be undertaken, because this technology cannot measure fluorescent antibodies.
Like any good study, the one by Dragovic et al. not only provides important novel findings but also raises new questions. The authors point out that little difference exists in EVs between normal pregnant and preeclamptic women, possibly because only plasma from women with late-onset preeclampsia was available for the study. It is generally accepted that early and late-onset preeclampsia differ in pathogenesis and that an inherent defect of the trophoblast is typical for the early onset disease. Therefore, it will be interesting to see a study on EVs and, especially, STBMs in plasma from patients with normal pregnancy in comparison to those from patients with early onset preeclampsia. Future development of the NTA technology may include detection of fluorescence, allowing further phenotyping of nanoparticles using fluorescent antibodies. 
